Patent №
US 7,517,880
Granted
2009-04-14
Filed 2002
Owner
BAYER CORPORATION
+2 more
Lab
—
AI components
1
evo
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
10060396
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
AI classification
Ownership
BAYER CORPORATION
assignment · 128510609
BAYER PHARMACEUTICALS CORPORATION
assignment · 141250545
BAYER HEALTHCARE LLC
assignment · 218930336
Assignors
MILLER, SCOTT, OSTERHOUT, MARTIN, DUMAS, JACQUES, KHIRE, UDAY, LOWINGER, TIMOTHY B., SCOTT, WILLIAM J., SMITH, ROGER A., WOOD, JILL E., GUNN, DAVID E., HATOUM-MOKDAD, HOLIA, RODRIGUEZ, MARTHA, SIBLEY, ROBERT, +3 more
On an employer assignment, the assignors are typically the inventors.